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The nonstructural protein 5A (NS5A) of the hepatitis C virus (HCV) has been shown to interact with a variety of cellular
proteins and implicated in the regulation of cell growth, interferon resistance, and other cellular signaling pathways, but the
role of NS5A in HCV pathogenesis has not been firmly established. To further characterize this multifunctional protein, we
instigated the studies of the subcellular localization of NS5A in a hepatoma cell line. NS5A was localized to the perinuclear
membrane structures, including the endoplasmic reticulum (ER) and the Golgi apparatus, by immunofluorescence staining
and confocal microscopy. In addition, it was also associated with the surface of cytoplasmic globular structures when
expressed alone or as a part of the NS3-5B polyprotein. Oil red O staining revealed that these globular structures were lipid
droplets, where the HCV core protein was also localized. The association of NS5A with intracellular membrane was further
confirmed by membrane flotation analysis. To determine whether NS5A interacts with any cellular lipid-binding protein, we
performed yeast two-hybrid screening in both HepG2 and human liver cDNA libraries. Apolipoprotein A1 (apoA1), one of the
protein components of high-density lipoprotein (HDL) particles, was identified by two independent screening processes. The
interaction between NS5A and apoA1 was confirmed by both in vitro pull-down and in vivo coimmunoprecipitation experi-
ments. Immunofluorescence staining revealed a significant colocalization of NS5A and apoA1 in the Golgi apparatus. Our
results established an association of NS5A with lipid droplets and apoA1, suggesting that NS5A, together with the core
protein, may play a role in the pathogenesis of the derangement of lipid metabolism, contributing to liver steatosis commonly
observed in hepatitis C. © 2002 Elsevier Science
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Hepatitis C virus (HCV) has emerged in the recent
years to be an important human pathogen associated
with non-A, non-B hepatitis. HCV infection is prevalent in
about 2% of the world population and is the leading
cause of chronic hepatitis and liver cirrhosis. As a mem-
ber of the Flaviviridae family, HCV contains a positive-
sense, single-stranded RNA genome of approximately
9.5 kb. The viral genome encodes a single polyprotein of
about 3010 amino acids, which is proteolytically pro-
cessed by a combination of host- and virus-encoded
proteases into at least 10 viral structural and nonstruc-
tural (NS) proteins arranged in the order of (NH3)-C-E1-
E2-p7-NS3-NS4A-NS4B-NS5A-NS5B-(COOH) (Grakoui et
al., 1993; Lohmann et al., 1996). Most of the nonstructural
proteins (NS2-5B) are probably involved in viral replica-
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198tion; for example, NS2, NS3, and NS4A have proteo-
lytic activities, whereas NS5B is an RNA-dependent
RNA polymerase responsible for HCV RNA replication.
But the possible functions of NS4B and NS5A remain
enigmatic.
NS5A is a phosphoprotein (Tanji et al., 1995), which
appears to possess multiple and diverse functions in
HCV replication, interferon (IFN) resistance, and HCV
pathogenesis. Based on the studies using a subgenomic
HCV replicon, NS5A has recently been implicated in viral
RNA replication (Blight et al., 2000). We have previously
shown that NS5A and NS5B together bind to a human
vesicle-associated membrane protein (VAMP)-associat-
ed protein of 33 kDa (hVAP33), suggesting that NS5A
may be part of the membrane-associated viral replication
complex (Tu et al., 1999). NS5A contains a putative nu-
clear localization signal, although the full-length NS5A is
retained in the cytoplasm (Ide et al., 1996). The N termi-
nus truncated, but not the full length; NS5A is a potent
transcriptional activator (Chung et al., 1997; Kato et al.,
1997; Tanimoto et al., 1997). However, whether this trans-
activation activity is related to HCV RNA synthesis is not
clear. Interestingly, a recent report has indicated that the
full-length NS5A can be cleaved by cellular caspase-like
199HCV NS5A AND LIPID ASSOCIATIONproteases into the truncated forms that possess trans-
activation activity (Satoh et al., 2000).
NS5A has been proposed to contain an interferon-
sensitivity-determining region (ISDR) in the central part of
the protein, which may be one of the determinants of the
response to IFN treatment in patients infected with cer-
tain genotype 1b isolates (Enomoto et al., 1996; Fukuma
et al., 1998). This region has also been found to mediate
the binding of NS5A to the IFN-inducible double-
stranded (ds) RNA-dependent protein kinase (PKR), an
immediate early effector of the cellular antiviral response
induced by IFN (Gale et al., 1998). NS5A from IFN-resis-
tant strains of HCV genotypes 1a and 1b can repress the
actions of PKR, whereas mutations within the ISDR,
which were identified in IFN-sensitive strains of HCV,
rendered NS5A inactive. Recently, NS5A has been
shown to induce a CXC chemokine, interleukin 8, leading
to a partial inhibition of the antiviral effects of IFN (Polyak
et al., 2001). Thus, it appears that NS5A employs at least
two different mechanisms to counteract the effects of
IFN. In addition, NS5A may have a direct effect on the
pathogenesis of HCV-associated liver disease. For ex-
ample, NS5A contains antiapoptotic and oncogenic ac-
tivities, which may contribute to the development of HCC
(Gale et al., 1999; Ghosh et al., 2000a, 1999). These
oncogenic potentials of NS5A can be attributed to its
interaction and inhibition of the tumor suppressor pro-
teins, PKR (Gale et al., 1999) and p53 (Majumder et al.,
2001). However, a recent study found no effects of NS5A
on dsRNA-induced apoptosis (Ezelle et al., 2001). Fur-
thermore, NS5A interacts with growth factor receptor-
bound protein 2 (Grb-2) adaptor protein (Tan et al., 1999),
a cellular transcription factor Snf2-related CREB (cAMP
receptor-binding protein)-binding protein activator pro-
tein (SRCAP) (Ghosh et al., 2000b), and karyopherin b3
(Chung et al., 2000), and, thus, may perturb various cel-
lular signaling and metabolic pathways and contribute to
HCV-related liver disease.
The potential interaction of NS5A with so many differ-
ent cellular proteins suggests that NS5A could be widely
distributed inside the cells. Previous studies have sug-
gested an association of NS5A with the ER and the Golgi
(Polyak et al., 1999; Tu et al., 1999), which is consistent
with its possible role in HCV replication (Blight et al.,
2000; Pietschmann et al., 2001). However, this localiza-
tion will not likely explain all of the purported functions of
NS5A. Moreover, the subcellular localization of NS5A
has not been studied extensively in hepatocytes, the
natural reservoir for HCV infection. We, therefore, per-
formed systematic studies of the subcellular localization
of NS5A by confocal microscopy in a hepatoma cell line,
HuH7. We found that NS5A was localized not only to the
ER and the Golgi apparatus, but was also colocalized
with the HCV core protein on cytoplasmic lipid droplets.
Furthermore, it could interact with apolipoprotein A1
(apoA1), which is a component of HDL particles. There-fore, NS5A appears to be capable of interacting with
multiple components of cellular lipid metabolic path-
ways, and, together with the core protein, may thus
contribute to HCV-associated steatosis.
RESULTS
NS5A colocalizes with the HCV core protein on lipid
droplets in addition to the ER and the Golgi apparatus
To explore the potential roles of NS5A in HCV patho-
genesis, we examined the subcellular localization of
NS5A in the context of other NS proteins by immunoflu-
orescence staining and confocal microscopy in a human
hepatoma cell line, HuH7. HuH7 cells transfected with
pSI/NS3-5B, which expresses NS3 through NS5B, were
fixed under a condition that better preserves the lipid
architecture of the cells. The localization of NS5A was
determined by immunostaining with a monoclonal anti-
body against NS5A. Calreticulin (Stendahl et al., 1994)
and the beta coat protein (bcop) (Waters et al., 1991)
were used as markers for the ER and the Golgi appara-
tus, respectively. Similar to NS5A alone (Polyak et al.,
1999) (data not shown), NS5A expressed as a part of the
NS polyprotein was localized to the ER (Figs. 1a–d) as
well as the Golgi apparatus (Figs. 1e–h). This result is
consistent with the previous findings that NS5A binds to
hVAP33, which is mainly localized to the ER and the Golgi
apparatus (Tu et al., 1999), and that NS5A is part of the
HCV replication machinery (Blight et al., 2000; Pi-
etschmann et al., 2001), which is likely membrane bound.
Interestingly, NS5A was also found on the circumference
of distinct globular structures, which were not stained by
the ER marker (arrows in Figs. 1a–d). These structures
collapsed when the cells were subjected to acetone
treatment (data not shown), but were not affected by low
concentrations of detergent, such as 0.1% Triton X-100,
suggesting that these structures may contain lipids.
Previous reports have shown that the HCV core pro-
tein is associated with lipid droplets in several cell lines,
including HepG2 (Barba et al., 1997; Hope and
McLauchlan, 2000). The contents of these droplets were
determined to be mainly triacylglycerols and/or choles-
terol esters (Barba et al., 1997), which can be identified
by oil red O staining (Hope and McLauchlan, 2000;
Ramirez-Zacarias et al., 1992). We, therefore, stained the
cells with oil red O to see whether these globular struc-
tures were lipid droplets. Indeed, the periphery as well
as the contents of these structures were intensely
stained with oil red O, indicating that they are most likely
lipid droplets (Fig. 2A, a–d). In cells that contain abun-
dant lipid droplets, the association of NS5A with lipid
droplets was even more prominent than that with the ER
or the Golgi. Similarly, some of the HCV core protein was
also shown to be associated with the surface of lipid
droplets (Fig. 2A, e–h). When NS5A and the core protein
were coexpressed, they displayed a significant colocal-
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these cells, the fluorescence intensity was lowered to
ensure a discernible demonstration of NS5A on lipid
droplets, but the relatively fainter staining on other struc-
tures, such as the ER, could not be shown clearly under
FIG. 1. The subcellular localization of NS5A in HuH7 cells. HuH7
cells were transfected with the construct expressing the NS3-5B
polyprotein, pSI/NS3-5B. Two days after transfection, the cells were
double stained with either the rabbit polyclonal antibody against the ER
marker, calreticulin (a), or the rabbit polyclonal antibody against the
Golgi marker, bcop (f), and the monoclonal antibody against NS5A (b,
e). The arrows indicate the localization of NS5A on cytoplasmic glob-
ular structures. The superimposed images are shown in (d) and (h). The
phase contrast images are shown in (c) and (g). Bar: 5 mm.this condition.
We also examined the localization of core and NS5A inBHK21 and CHO cells, which have fewer and smaller
lipid droplets. The expression of the core protein in-
creased the number of lipid droplets in these two cell
lines (data not shown), consistent with the previous find-
ings in CHO cells (Barba et al., 1997). When coexpressed
with the core protein in BHK21 cells, NS5A colocalized
with core on the surface of lipid droplets (Fig. 2B, e–h,
arrowheads). NS5A alone, however, did not induce the
appearance of lipid droplets. Instead, it exhibited a more
diffuse pattern predominantly in the perinuclear region,
most likely being associated with the ER and the Golgi
(Fig. 2B, f and h, arrows). We did not observe an apparent
synergism between NS5A and core in terms of induction
of lipid droplets. Similar results were also obtained in
CHO cells (data not shown).
When NS5A was expressed as part of the NS3-5B
polyprotein in HuH7 cells, it was detected on the surface
of lipid droplets as well (note yellow rings in Fig. 3d). In
contrast, neither NS3 (Figs. 3e–h) nor NS5B (data not
shown) colocalized with lipid droplets. Taken together,
these findings indicate that NS5A colocalizes with the
core protein on the surface of lipid droplets in both
hepatic and nonhepatic cell lines.
Association of NS5A with membrane fractions
Immunofluorescence staining and confocal analysis
indicated that NS5A is localized to cytoplasmic mem-
brane structures, such as the ER and the Golgi as well as
lipid-containing structures, such as lipid droplets. To
confirm the association of NS5A with lipid-containing
membranes, we performed membrane flotation analysis
to separate membrane and cytosolic fractions as previ-
ously described (Sanderson et al., 1994). The membrane-
containing materials float to the top of the sucrose gra-
dient, while the cytosolic fractions remain at the bottom.
The sucrose gradient was collected from the top to the
bottom into nine fractions. The presence of NS5A in each
fraction was determined by immunoblotting using the
monoclonal anti-NS5A antibody. As shown in Fig. 4A,
NS5A was found predominantly in the membrane frac-
tion (fraction 2). The core protein was also detected in
both membrane and cytosolic fractions as previously
reported (Matsumoto et al., 1996), but cotransfection of
core with NS5A did not change the distribution of NS5A
in different fractions (data not shown). An ER marker,
glucose-regulated protein 78 (GRP78) (Munro and Pel-
ham, 1986) was found to be located in the membrane
fraction (Fig. 4A, fraction 2) and also in the cytosolic
fractions (fractions 6–9). When the cell lysates were
treated on ice with 1% NP-40, a nonionic detergent,
GRP78 was only observed in the cytosolic fractions (Fig.
4B), indicating a complete release of the ER-resident
protein upon membrane disruption. In contrast, only a
small percentage of the NS5A protein dissociated from
the membrane and moved to the cytosolic fractions (Fig.
d imag
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present in detergent-insoluble complexes. This observa-
tion is consistent with the recent finding that proteins
localized on lipid droplets are insoluble in cold nonionic
detergents (Pol et al., 2001). These results provide bio-
FIG. 2. NS5A colocalizes with the HCV core protein on lipid drople
transfected with pcDNA3.1/NS5A or pcDNA3.1/core. Two days after tran
NS5A (b) or the rabbit polyclonal antibody against core (f), respectively.
Colocalization of NS5A and core. HuH7 (a–d) and BHK21 (e–h) cells we
6 transfection reagent. Two days after transfection, the cells were doub
mouse monoclonal antibody against NS5A (b and f). The superimpose
(c) and (g). Bar: 5 mm.chemical evidence that NS5A is associated with intra-
cellular membrane structures, including lipid droplets.Identification of apoA1 as an NS5A-binding protein by
yeast two-hybrid screening
The association of NS5A with lipid droplets suggests
that NS5A may interact with components of lipid meta-
Colocalization of NS5A and core on lipid droplets. HuH7 cells were
n, the cells were stained with the mouse monoclonal antibody against
roplets were stained with oil red O (a and e) after immunostaining. (B)
ansfected with pcDNA3.1/NS5A and pcDNA3.1/core using the FuGene
ed with the rabbit polyclonal antibodies against core (a and e) and the
es are shown in (d) and (h). The phase contrast images are shown ints. (A)
sfectio
Lipid d
re cotr
le stainbolic pathways. To identify such components, we per-
formed two independent yeast two-hybrid screenings to
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When NS5A of genotype 1a was used as the bait to
screen a HepG2 cDNA library, seven positive clones
were obtained (Tu et al., 1999), one of which was iden-
tified as human apoA1. The previously reported NS5A-
binding protein, hVAP-33, was also identified by the
same screening (Tu et al., 1999). The other screening
using NS5A of genotype 1b as the bait in a human liver
cDNA library resulted in 12 positive clones, three of
which were apoA1. ApoA1 is one of the major protein
components of the HDL particles (Fruchart and Ailhaud,
1992). The other protein component of HDL is apoA2,
which has been shown to interact with the HCV core
protein (Sabile et al., 1999). The function of apoA2, how-
ever, is still not clear.
The specificity of the interaction between NS5A and
apoA1 was further verified by cotransformation of yeast
with the pACT-2/apoA1 clone and various NS5A geno-
type 1b constructs in plasmid pAS2-1 (Fig. 5). As ex-
pected, apoA1 interacted with the full-length NS5A. De-
letion of the C-terminal 44 amino acids (aa) of NS5A
(NS5A-DC) or of the ISDR (NS5A-DISDR) did not affect
the binding to apoA1. The N-terminal 224 aa of NS5A
(N-NS5A) alone was sufficient for binding. In contrast,
ISDR alone (ISDR) did not interact with apoA1. As nega-
tive controls, the plasmid vector containing the GAL4
DNA-binding domain (BD) alone or lamin C did not inter-
act with apoA1. Some truncated NS5A constructs con-
taining the DNA-binding domain have only been shown
previously to activate b-gal in the absence of the activa-
tion domain (AD) construct (Chung et al., 1997; Kato et al.,
1997; Tanimoto et al., 1997), but no autonomous activa-
tion was observed for the NS5A constructs used in this
study (data not shown).
NS5A interacts with apoA1 in vitro
To confirm that HCV NS5A can interact with apoA1
directly, we performed GST-pull-down assays in vitro.
The full-length apoA1 and three truncation mutants (D1,
D2, and D3) were expressed as GST-fusion proteins and
incubated with in vitro translated, 35S-labeled NS5A. As
shown in Fig. 6A, GST-apoA1 (lane 3), but not GST alone
(lane 2), was able to pull down NS5A. Interestingly,
apoA2, which is another protein component of the HDL
particles and interacts with the HCV core protein, also
bound NS5A, although the interaction was weaker than
that between NS5A and apoA1 (lane 7). Computer-aided
analysis showed that apoA1 and apoA2 contain homol-
ogous amino acid sequences, which may explain the
binding of NS5A to both apolipoproteins (Shelley et al.,
1985). No interaction was detected between NS5B and
apoA1 or A2 (lanes 8–10), indicating that the in vitro
interactions between NS5A and apolipoproteins are spe-
cific.
ApoA1 consists of repetitive 22-aa segments that formamphipathic alpha helices, capable of lipid and protein
binding (Segrest et al., 1992). The N-terminal aa 43–126
of apoA1 has been shown to be responsible for protein–
protein interaction (Jonas et al., 1990), whereas the C-
terminal aa 190–243 is critical for lipid binding, self-
association, and lipoprotein interaction (Ji and Jonas,
1995; Schmidt et al., 1995; Segrest et al., 1992). Moreover,
the helical structures throughout the apoA1 protein are
influenced by changes in other parts of the protein and
by lipid binding (Davidson et al., 1996). To determine
which region of apoA1 is responsible for NS5A binding,
three truncated constructs of apoA1 (Fig. 6) were used in
GST-pull-down assay. Truncation of the N-terminal 66 aa
of apoA1 (apoA1D2) did not affect its binding to NS5A
(Fig. 6A, lane 5), whereas deletion of the C-terminal 76 aa
only slightly reduced the binding (apoA1D1, lane 4), sug-
gesting that the middle domain is the NS5A-binding
sequence. However, the central domain of apoA1
(apoA1D3) alone binds to NS5A only weakly, suggesting
that the neighboring sequences are also important for
maintaining the NS5A-binding properties.
NS5A interacts with apoA1 in mammalian cells
To demonstrate the potential interaction of NS5A with
apoA1 in cells, we performed coimmunoprecipitation
experiments for NS5A and apoA1 in Cos7 cells. The
Flag-tagged NS5A was coexpressed with apoA1 from
T7-expression plasmids, coupled with infection with re-
combinant vaccinia viruses (vTF7-3) expressing T7 poly-
merase. Cell lysates were immunoprecipitated with the
monoclonal anti-Flag antibody (M2 beads). The immuno-
precipitates were separated by SDS-PAGE, followed by
immunoblotting with a goat polyclonal anti-apoA1 anti-
body. ApoA1 was shown to coimmunoprecipitate with
Flag-NS5A (Fig. 7, lane 4), but not NS5B (lane 5), although
the expression of Flag-NS5B was comparable to that of
Flag-NS5A. When apoA1 was expressed alone, it could
not be precipitated by the anti-Flag antibody (lane 3).
These results further demonstrate that apoA1 can spe-
cifically interact with NS5A in mammalian cells.
Colocalization of NS5A with apoA1 in HuH7 cells
The results shown above indicate that NS5A can in-
teract with apoA1 both in vitro and in vivo. To evaluate the
possibility of such an interaction in intact cells, we ex-
amined the subcellular localization of apoA1 with NS5A
by immunostaining. Because the level of intracellular
apoA1 was too low, probably as a result of rapid secre-
tion, to produce an unequivocal staining, apoA1 or A2
was cotransfected with Flag-NS5A into HuH7 cells. Both
apoA1 and A2 were found to be clustered in the perinu-
clear region and colocalized with the Golgi complex
(data not shown), which is consistent with the previous
finding that apoA1 is predominantly associated with the
trans-Golgi network (Banerjee et al., 1997). We did not
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lets. However, both of them were colocalized with a
portion of NS5A (Fig. 8), most likely on the Golgi appa-
ratus, supporting a possible interaction between NS5A
and these two apolipoproteins. Under the same condi-
tion, NS5A was also detected on the surface of lipid
droplets (Figs. 8a–d, arrows). Similar results were ob-
tained in BHK21 cells or when NS5A was expressed as
a part of the NS3-5B polyprotein (data not shown). These
results confirmed that only a portion of the intracellular
pool of NS5A is associated with apoA1 and apoA2 on the
Golgi apparatus, which is consistent with the multifunc-
tional nature of NS5A.
DISCUSSION
HCV infection is often associated with the occurrence
of liver steatosis (Baiocchi et al., 1998; Fujie et al., 1999).
The involvement of HCV core protein in the development
of steatosis has been suggested by its localization on
lipid droplets and its interaction with apoA2 (Barba et al.,
1997; Sabile et al., 1999). In this report, we showed that
NS5A could be another HCV protein that plays a role in
HCV-associated liver steatosis. NS5A is colocalized with
the HCV core protein on lipid droplets and interacts with
apoA1, which is a lipid-binding protein and one of the
major components of HDL particles. These properties
suggest that NS5A may affect cellular lipid metabolism
by at least two different mechanisms, and that NS5A,
together with core, may contribute to the development of
liver steatosis.
Earlier studies have reported that NS5A is localized to
cytoplasmic membrane structures (Kim et al., 1999;
Polyak et al., 1999; Selby et al., 1993; Tu et al., 1999), but
the exact localization of NS5A has not been determined.
In this study, we identified these membranes as the ER
and the Golgi apparatus by immunofluorescence stain-
ing. Furthermore, both cytological and biochemical stud-
ies showed that NS5A was also present on lipid droplets.
Previous failures to identify such an association could
have been due to the disruption of lipid droplets by
acetone or methanol in the fixation procedures. In fact,
the core protein was associated only with the ER mem-
brane when it was expressed in cells grown in lipid-
deficient medium (Hope and McLauchlan, 2000). In ad-
dition, the localization of NS5A in HuH7 cells was also
affected by the differences in number, size, and distribu-
tion of lipid droplets. In cells where most of the cyto-
plasm was occupied by large lipid droplets, the NS5A
signal was found to be concentrated on the surface of
lipid droplets (e.g., Figs. 2A, a–d). A relatively smaller
amount of NS5A was associated with the ER and the
Golgi in these cells, which could be seen only when the
fluorescence intensity was enhanced.Electron microscopy of the HuH7 cells containing a
self-replicating subgenomic replicon revealed an asso-ciation of HCV NS proteins with the ER, but not with
lipid-containing vesicles (Pietschmann et al., 2001). How-
ever, in that study, a mixture of the antibodies against
several NS proteins were used; thus, it is not clear
whether NS5A was specifically detected. It is also pos-
sible that the localization of NS5A is dependent on other
cellular conditions. The exact nature of this difference
remains to be clarified. Regardless, the wide distribution
of NS5A in different subcellular components is consis-
tent with its purported multiple functions.
Lipid droplets occur in all mammalian cell types and
serve as energy storage sites (Brown, 2001; van Meer,
2001). They consist of a core of triacylglycerols and
cholesterol esters, which is synthesized in the ER, sur-
rounded by a phospholipid monolayer, which is also
derived from the ER (Brown, 2001; van Meer, 2001). A
number of proteins, such as perilipin (Blanchette-Mackie
et al., 1995), adipophilin (Brasaemle et al., 1997), TIP47
(Wolins et al., 2001), and caveolin (Fujimoto et al., 2001;
Ostermeyer et al., 2001; Pol et al., 2001), have been
shown to be present on the surface of lipid droplets.
Binding of proteins to lipid droplets is probably hydro-
phobic in nature as it was resistant to the treatment of
cold nonionic detergents (Pol et al., 2001) or carbonate
(Wolins et al., 2001).
Presumably, these lipid droplet-associated proteins
play key roles in the structure and function of lipid drop-
lets, but very little is known about them. A recent study
reported that perilipin could regulate the number, distri-
bution, and contents of lipid droplets (Brasaemle et al.,
2000). Significantly, we found that the association of
NS5A with membrane structures was also resistant to
detergent treatments. It is not clear whether NS5A or
core interact with the lipid droplets by directly binding to
the lipids or through the interactions with other surface
proteins. Conceivably, these HCV proteins may also af-
fect the structure and function of lipid droplets. We in-
deed observed an increase in the number of lipid drop-
lets upon the expression of the HCV core protein as
previously shown by Barba et al. (1997). In contrast,
NS5A did not appear to possess the ability to induce the
formation of lipid droplets. As a result, when NS5A alone
was expressed in BHK21 cells, it was localized in the
perinuclear region, most likely to be associated with the
ER and the Golgi (Fig. 2B). Nevertheless, NS5A still
showed strong affinity for the lipid droplets induced by
the expression of core in cells coexpressing NS5A and
core. There was no gross difference observed with the
lipid droplets in cells expressing core alone or coex-
pressing NS5A and core; however, it cannot be ruled out
that NS5A can affect the stability or change the contents
of the core-induced lipid droplets. More studies are
needed to understand the functions of NS5A in lipid
droplet formation.ApoA1 is mainly synthesized and actively secreted by
the liver (Brouillette and Anantharamaiah, 1995). It is one
204 SHI ET AL.of the major protein components of the HDL particles,
whose major lipid components consist of triacylglycerols
and cholesterol esters. The primary function of apoA1
and HDL is the regulation of serum cholesterol levels by
transporting cholesterol from peripheral tissues to the
liver through a process known as reverse cholesterol
FIG. 3. NS5A is associated with lipid droplets in the presence of
other NS proteins. HuH7 cells were transfected with pSI/NS3-5B. Two
days after transfection, the cells were immunostained with the mouse
monoclonal antibody against NS5A (b) or the mouse monoclonal anti-
body against NS3 (f). Lipid droplets were stained with oil red O (a and
e) after immunostaining. The superimposed images are shown in (d)
and (h). The phase contrast images are shown in (c) and (g). Bar: 5 mm.transport (Fruchart and Ailhaud, 1992). Furthermore,
apoA1 and apoA2 have been shown to regulate hepaticlipase-mediated hydrolysis of triacylglycerols and phos-
pholipids in HDL particles (Boisfer et al., 1999; Hime et
al., 1998, 2001; Mowri et al., 1996, 1992; Shinomiya et al.,
1982; Weng et al., 1999; Zhong et al., 1994). Because
triacylglycerols, cholesterol esters, and/or phospholipids
are also the components of lipid droplets as indicated by
oil red O staining, apoA1 and apoA2 may affect the
formation and composition of lipid droplets through the
regulation of intracellular metabolism of fatty acids. The
HCV proteins, NS5A and core, may, in turn, have an effect
on lipid metabolism through their interactions with
apoA1 and apoA2. Although we did not observe a local-
ization of apoA1 or apoA2 on lipid droplets, it is still
possible that a small amount of them is present, which
can directly influence the properties of lipid droplets.
Indeed, detection of a fraction of apoA1 in other parts of
the cytoplasm has been documented previously (Hamil-
ton et al., 1990). Alternatively, NS5A may interact with yet
another unidentified lipid-binding molecule. Regardless
of the mechanism, the fact that NS5A interacts with lipids
and lipoproteins strongly suggests that it may change
lipid homeostasis in hepatic cells, leading to the devel-
opment of liver steatosis.
Intriguing evidence from clinical studies of alcohol-
induced liver disease indicates that serum apoA1 levels
change with disease progression, with an elevation ob-
served in patients with steatosis, a reduction in those
with fibrosis, and a further decline in those with cirrhosis
(Poynard et al., 1995). Hepatic steatosis has also been
recognized as a characteristic of HCV infection and re-
infection after liver transplantation (Baiocchi et al., 1998).
A recent evaluation of blood lipid composition in patients
with chronic hepatitis C treated by IFN showed that the
levels of apoA1 and HDL are independent predictive
factors for response to treatment (Soardo et al., 1995).
Overall, these results suggest that hepatic lipid metabo-
lism is a potential target for HCV proteins in viral patho-
genesis. Transgenic mice expressing the core protein
develop liver steatosis (Moriya et al., 1998, 1997). The
findings that both core and NS5A are colocalized on lipid
droplets and that both of them interact with apoA2 in
addition to the interaction of NS5A with apoA1 suggest
that core and NS5A may together affect lipid metabolism
and contribute to steatosis.
ApoA1 possesses extensive secondary structure in
the form of alpha helices. The amphipathic nature pro-
vides apoA1 with the ability to perturb various lipid bi-
layers. Consequently, apoA1 has been shown to possess
antiviral and immunosuppressive activities, most likely
through the perturbation of cellular membranes. Antiviral
functions mediated by apoA1 include inhibition of human
immunodeficiency virus and herpes simplex virus-in-
duced cell fusion (Owens et al., 1990; Srinivas et al.,
1990), neutralization of xenotropic type C retrovirus (Kane
et al., 1979), and lysis of Trypanosoma brucei mem-
branes (Gillett and Owen, 1992). Another apolipoprotein,
y) fracti
205HCV NS5A AND LIPID ASSOCIATIONapolipoprotein-H, has been shown to bind the surface
antigen of hepatitis B virus (Mehdi et al., 1994). Further-
more, an earlier report indicated that serum lipoproteins,
including HDL, could inhibit lymphocyte proliferation
stimulated by lectins or allergenic cells (Morse et al.,
1977). Our finding that NS5A interacts with apoA1 and
apoA2 suggests a potential perturbation of some or all of
the functions of these apolipoproteins.
The association of HCV with lipids may also be impor-
tant in the viral life cycle. HCV has been shown to bind
low-density lipoprotein (LDL) and its receptor, very low-
density lipoprotein (VLDL) and, to a lesser degree, HDL
(Agnello et al., 1999; Thomssen et al., 1993; Wunschmann
et al., 2000). Conceivably, the interaction between NS5A
and apoA1 may affect HCV binding or entering the target
cells.
MATERIALS AND METHODS
Plasmid construction
For expression in mammalian cells, NS5A (genotype
1a)-coding sequence, together with a Flag sequence
FIG. 4. Membrane flotation analysis of NS5A. HuH7 cells were transf
were fractionated by equilibrium sucrose gradient centrifugation as des
Centricon and analyzed on a 12.5% polyacrylamide gel, followed by imm
were numbered from 1 to 9 in the order of top to bottom (light to heav
NP-40 for 20 min on ice before sucrose gradient centrifugation.
FIG. 5. Interaction between NS5A and apoA1 in yeast. The full-length
and truncation mutants of NS5A from genotype 1b were cloned into the
pAS2-1 vector and transformed with pACT2-apoA1 into Saccharomyces
cerevisiae Y190 cells using the lithium chloride method according to
the manufacturer’s instructions. The yeast cells were streaked on
histidine-containing medium (1HIS) or histidine-deficient medium con-
taining 25 mM 3-amino triazole (2HIS13-AT). Yeast growth was ob-
served 4 days after transformation. NS5A-DC codes for a protein that
lacks the C-terminal 44 aa. N-NS5A represents the N-terminal 224 aa of
NS5A. pAS2-1 (empty vector) and pAS2-1-lamin C were used as neg-
ative controls.linked to its N terminus, was cloned into pcDNA3.1 (In-
vitrogen, Carlsbad, CA). The coding sequence of core
(genotype 1a) was also cloned into pcDNA3.1. The Flag-
tagged full-length NS5B from genotype 1a used as a
control in coimmunoprecipitation was constructed in
pcDNA3.1. The NS3-NS5B (genotype 1b) construct ex-
pressing an NS3-NS4A-NS4B-NS5A-NS5B polyprotein
was cloned into pSI (Promega, Madison, WI). ApoA1 and
apoA2 were cloned into pcDNA3.1 for their expression in
mammalian cells. The plasmids used for expressing glu-
tathione S-transferase (GST) fusion proteins of apoA1 or
apoA2 in Escherichia coli were constructed in the pGEX-
4T-1 vector (Novagen, Madison, WI).
Antibodies
The mouse monoclonal antibodies against NS5A and
NS3 were purchased from Biodesign (Saco, Maine) and
Vector Laboratories (Burlingame, CA), respectively. The
rabbit polyclonal antibody against the HCV core protein
was a gift from Dr. Jim Ou at the University of Southern
California (Los Angeles, CA). The rabbit polyclonal anti-
bodies against calreticulin and bcop were obtained from
Affinity Bioreagents (Golden, CO). The mouse monoclo-
nal antibody against GRP78 was purchased from Stress-
Gen (Victoria, Canada). The goat polyclonal antibody
against apoA1 and apoA2 were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). The mouse mono-
clonal antibody against apoA1 was generously provided
by Dr. Carole L. Banka at the Scripps Research Institute
(La Jolla, CA). The polyclonal antibody against the Flag
epitope was purchased from Zymed (San Francisco, CA).
The M2 beads used for the immunoprecipitation of Flag-
tagged proteins were obtained from Sigma (St. Louis,
MO).
Immunofluorescence staining
Cells were plated in 8-well chamber slides at a density
4
ith pcDNA3.1/NS5A and harvested 48 h after transfection. Cell lysates
in Materials and Methods. Each fraction was concentrated in an YM-10
tting with a monoclonal antibody against NS5A or GRP78. The fractions
ons. (A) No detergent treatment. (B) Cell lysates were treated with 1%ected w
cribed
unobloof 5 3 10 cells per well and transfected with 0.2 mg of
each plasmid in each well using the FuGene 6 transfec-
that la
206 SHI ET AL.tion reagent according to the manufacturer’s instructions
(Roche Molecular Biochemicals, Indianapolis, IN). Two
days after transfection, slides were washed in PBS and
fixed in 4% formaldehyde for 20 min at room temperature,
followed by 15 min in 0.1% Triton X-100 in PBS. Primary
antibodies were diluted in 5% BSA and incubated with
cells for 1 h at room temperature. After three washes in
PBS, fluorescein-conjugated secondary antibodies (Jack-
son ImmunoResearch Laboratories, West Grove, PA)
were added to cells at a 1:200 dilution for 1 h at room
temperature. To stain lipids, slides were rinsed in 60%
isopropanol, incubated in 5 mg/ml oil red O (Fisher Sci-
entific, Pittsburgh, PA) in 60% isopropanol for 2 min at
room temperature, and rinsed in 60% isopropanol again.
After staining, slides were washed in PBS and mounted
in ProLong Antifade (Molecular Probes, Eugene, Ore-
gon). Confocal microscopy was performed on a Zeiss
Confocal Laser Scanning Microscope LSM 510. Image
analysis was performed using the standard system op-
erating software provided with the microscope. Colocal-
ization of green (FITC) and red (TRITC) signals in a single
FIG. 6. In vitro interaction between NS5A and apolipoproteins. (A) G
apoA2 were expressed as GST-fusion proteins in BL21 and purified w
were incubated with the in vitro translated, 35S-labeled NS5A or NS5
glutathione beads, and analyzed on a 12.5% SDS-PAGE. One tenth of t
input. The numbers below each lane show the quantitation of signals in
assay are summarized in B.pixel produces yellow while separated signals remain
green or red.Membrane flotation assay
HuH7 cells in 100-mm plates were transfected with 10
mg each of pcDNA3.1/NS5A, pcDNA3.1/core, or both us-
ing the FuGene 6 transfection reagent. Two days after
transfection, the cells were washed twice in ice-cold PBS
and harvested for membrane flotation assay as previ-
ously described (Sanderson et al., 1994). The cells were
first lysed in 1 ml of hypotonic buffer (10 mM Tris-HCl, pH
7.5, 10 mM KCl, 5 mM MgCl2) and passed through a
25-gauge needle 20 times. The nuclei and unbroken
cells were removed by centrifugation at 1000 g for 5 min
in a microfuge at 4°C. The supernatant was separated
into two 0.5-ml aliquots, one of which was incubated with
1% NP-40 on ice for 20 min. Each aliquot was then mixed
with 3 ml of 72% sucrose in low salt buffer (LSB, 50 mM
Tris-HCl, pH 7.5, 25 mM KCl, 5 mM MgCl2). The mixture
was overlaid with 4 ml of 55% sucrose in LSB, followed
by 1.5 ml of 10% sucrose in LSB. The sucrose gradient
was centrifuged at 38,000 rpm in a Beckman SW41Ti
rotor for 14 h at 4°C. One-milliliter fractions were taken
l-down assay. ApoA1 and its truncation mutants (D1, D2, and D3) and
athione beads. Equal amounts of these GST-fusion proteins on beads
°C for 2 h. The complexes were washed five times, eluted from the
itro translated products used in GST-pull down are shown as the 10%
ne as a percentage of the 10% input. The results of the GST-pull-downST-pul
ith glut
B at 4
he in vfrom the top of the gradient and each was concentrated
by passing through a Centricon YM-10 filter unit (Milli-
207HCV NS5A AND LIPID ASSOCIATIONpore, Bedford, MA). The pellet was resuspended in SDS
sample buffer and analyzed on a 12.5% polyacrylamide
gel.
Yeast two-hybrid screening
Two independent yeast two-hybrid screenings were
carried out, one of which used NS5A of genotype 1a as
the bait to screen an IFN-induced human hepatocyte
(HepG2) cDNA library (Tu et al., 1999). NS5A was cloned
into a yeast expression vector pGBT9, which contains
the GAL4 DNA-BD (Clontech, Palo Alto, CA) to express
NS5A as a DNA-BD-fusion protein. The HepG2 cDNA
library was expressed as fusion proteins to an activation
domain in pGAD10. The screening procedure was de-
scribed previously (Tu et al., 1999).
The second screening was performed using NS5A
from a genotype 1b patient who was nonresponsive to
IFN therapy as the bait to screen a human liver cDNA
library. The full-length NS5A genes were cloned sepa-
rately by RT-PCR from serum specimens obtained from
both IFN-responsive and nonresponsive patients as de-
FIG. 7. Coimmunoprecipitation of NS5A with apoA1. The Flag-tagged
NS5A and apoA1 were expressed in Cos7 cells with a vaccinia virus
expression system as described in Materials and Methods. The cyto-
plasmic extracts were prepared from the cells 16 h after transfection
and subjected to immunoprecipitation with the anti-Flag M2 beads. The
immunoprecipitates were separated on a 12.5% SDS-PAGE and immu-
noblotted with either the rabbit polyclonal antibody against Flag or the
goat polyclonal antibody against apoA1. The full-length Flag-tagged
NS5B was used as a negative control. One tenth of the cytoplasmic
extracts used in immunoprecipitation are shown as the 10% input.scribed (Polyak et al., 1999). The full-length NS5A or the
ISDR only were cloned into the GAL4 DNA-BD vectorpAS2-1 (Clontech). The human liver cDNA library was
cloned into the AD vector pACT2. The primer pair ISDR-
US1: 59-CCTTCCATGGCCCACATTACAGCAGAGACG-39
and ISDR-DS1: 59-ATCGGATCCTTATACCACCTTATTCTC-
TGA-39 was used to amplify the ISDR using the previ-
ously amplified full-length NS5A as a template. Prior to
library screening, the pAS2-1-NS5A and pAS2-1-ISDR
constructs were tested for autonomous activation of re-
porter genes. No autonomous activation of reporter
genes was observed with any of these constructs when
tested on two different occasions. Saccharomyces cer-
evisiae Y190 cells were cotransformed with pAS2-1-
NS5A plasmids and pACT2-cDNA libraries using the
lithium chloride method according to the manufacturer’s
instructions. At least 3 million transformants were
screened in each experiment. Cells were plated in me-
dium containing 25 mM 3-amino triazole. Clones were
selected based on their positivity for b-gal activity and
growth in histidine-deficient media upon retransforma-
tion into yeast. The AD plasmids were isolated from
positive clones that grew in histidine-deficient medium
and contained b-gal activity. The cDNA inserts in these
pACT2 plasmids were then sequenced and aligned with
known sequences in the GenBank.
GST-pull-down assay
pGEX-4T-1, pGEX-4T-1/apoA1, or pGEX-4T-1/apoA2
plasmids were transformed and expressed in E. coli
BL21 (DE3) (Novagen). The GST-pull-down experiment
was performed as described previously (Tu et al., 1999).
In brief, GST-fusion proteins on glutathione Sepha-
rose-4B beads were incubated with in vitro translated,
35S-labeled NS5A protein in 0.2 ml GST-binding buffer (40
mM HEPES, pH 7.5, 100 mM KCl, 20 mM 2-mercapto-
ethanol, 0.1% of NP-40) for 2 h at 4°C. The beads were
washed five times with the GST-binding buffer containing
0.3% NP-40. Proteins bound to beads were eluted by
boiling in Laemmli’s buffer for 5 min and separated on a
10% polyacrylamide gel. The in vitro translated full-length
NS5B of genotype 1a was used as a negative control.
Coimmunoprecipitation
Cos7 cells in 60-mm plates were infected with recom-
binant vaccinia virus vTF7-3 expressing T7 RNA polymer-
ase at a multiplicity of infection of approximately 10
(Fuerst et al., 1986). Two hours after infection, the cells
were transfected with 5 mg each of pcDNA3.1/NS5A and
pcDNA3.1/apoA1 using the calcium phosphate method.
pcDNA3.1/NS5B was used as a negative control. After
16 h incubation, the cytoplasmic proteins were prepared
and immunoprecipitated with the monoclonal anti-Flag
antibody crosslinked to Sepharose-4B beads (M2 beads,
Eastman Kodak Company, Rochester, NY). The precipi-
tates were washed five times, boiled in Laemmli’s sam-
ple buffer, and run on a 12.5% polyacrylamide gel. Immu-
208 SHI ET AL.noblotting was performed using polyclonal antibodies
against Flag and apoA1.
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